Abstract: The present invention relates to liquid crystal (LC) media comprising one or more polymerisable compounds as further specified in the description or claims and a self-alignment additive for vertical alignment. The media are adapted for use in LC displays, especially in LC displays of the polymer-sustained alignment type.

Abstract: Liquid crystal mixtures containing a photoalignment component A) containing a photoreactive mesogen of formula I, a liquid-crystalline component B) containing one or more nematogenic compounds, and a polymerizable component C) containing one or more polymerizable compounds of formula P, Pa-Spa-(Ap)n2-Spb-Pb??P and a method of producing such LC media, the use of such media in LC devices, and LC devices containing such a LC medium, and further a process for the fabrication of such liquid crystal displays and the use of the liquid crystal mixtures for the fabrication of such liquid crystal display.

Abstract: Compounds of the formula I, liquid-crystalline media which contain at least one compound of the formula I and electro-optical displays which contain the LC mixtures, especially for the self-aligning VA, PSA, PS-VA, PVA, MVA, PM-VA, HT-VA or VA-IPS mode in which R1, R2, ring A1, Z1, Z2, Sp, P, L1, L2, r1, r2, r3, m, n, p1 and p2 have the meanings indicated above.

Abstract: The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides or fragments thereof, and the use of such compositions as malaria vaccines.

Abstract: The invention relates to the compounds of the formula I and to a liquid-crystalline medium based on a mixture of polar compounds which contains at least one compound of the formula I in which in which R1, R2, ring A1, Z1, Z2, Sp, P, L1, L2, r1, r2, r3, m, n, p1 and p2 have the meanings indicated in Claim 1 and to the use of the LC mixtures in electro-optical displays, especially for the self-aligning VA, PSA, PS-VA, PVA, MVA, PM-VA, HT-VA or VA-IPS mode.

Abstract: The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides or fragments thereof, and the use of such compositions as malaria vaccines.

Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.

Abstract: The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides or fragments thereof, and the use of such compositions as malaria vaccines.

Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Abstract: The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a gene whose expression is up-regulated in liver stage parasites and whose function is not required for entry into hose hepatocytes.

Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.